secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semler Scientific, Inc. (—)
CIK:        0001554859
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001554859-23-000040
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Semler Scientific appoints CFO Renae Cormier, expects record Q2 revenue, plans 30% headcount reduction
--------------------------------------------------------------------------------

- Appointed Renae Cormier as CFO effective July 10, 2023; base salary $360,000 with 20% target incentive and 5,000 stock options at $25.47 per share.
- Expects record high quarterly revenues for Q2 2023, driven by continued sales of QuantaFlo for peripheral arterial disease testing.
- Plans to reduce headcount by ~30% by September 15, 2023, as part of strategic streamlining to improve operational efficiency.
- Anticipates quarterly OpEx reduction of $1.5M-$2.0M starting Q4 2023; severance costs of $0.7M-$0.9M to be paid by year-end 2023.
- Andrew B. Weinstein and Daniel E. Conger cease as principal financial and accounting officers; both remain for transition period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1554859/000155485923000040/0001554859-23-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1554859/000155485923000040/smlr-20230707x8k.htm
  HTML page:      https://secwatch.observer/filing/0001554859-23-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer